Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Hit Repeat

<< Previous

Bullboard Posts

Next >>

Comment by ENEMENEMYNEMOon Apr 17, 2024 9:30pm

112 Views

Post# 35995067

RE:RE:Hit Repeat

You can pull up messages on this board from 1 yr , 5 yr oh and even 10 years ago and they are all the same... "great outlook", "buyout coming", "great phase 2", "Phase 3 coming", Big pharma is paying attention"
This POS is a pay check for Matt and his cronies and pump and dump for Larry, Curly and Mo.
Cheers!

<< Previous

Bullboard Posts

Next >>

The long-term forecast for lithium stocks in 2024